Chargement en cours...
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
Ibrutinib is the first clinically approved inhibitor of Bruton’s tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and...
Enregistré dans:
| Publié dans: | Wien Klin Wochenschr |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Vienna
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7035304/ https://ncbi.nlm.nih.gov/pubmed/31414181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00508-019-1534-1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|